📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Lords Chloro Alkali to Hold EGM for MD Re-appointment and ₹1.5 Cr Base Salary Approval
Lords Chloro Alkali has scheduled an Extra Ordinary General Meeting (EGM) on March 18, 2026, to seek approval for the re-appointment of Ajay Virmani as Managing Director for a five-year term. The company is proposing a minimum fixed remuneration of ₹1.50 crore per annum each for the MD and Whole Time Director Madhav Dhir, effective April 1, 2026. A significant performance-linked incentive structure is also proposed, with bonuses ranging from 4% to 7% of Earnings Before Depreciation and Taxes (EBDT) based on specific profit milestones. Furthermore, the company seeks to exceed statutory limits, potentially paying total managerial remuneration in excess of 11% of net profits.
Key Highlights
Re-appointment of Ajay Virmani as Managing Director for 5 years effective July 12, 2026.
Proposed fixed annual remuneration of ₹1.50 crore each for the MD and Whole Time Director.
Tiered incentive structure based on EBDT, ranging from 4% (for EBDT >₹15cr) to 7% (for EBDT >₹100cr).
Seeking shareholder approval to pay total managerial remuneration exceeding 11% of net profits.
EGM scheduled for March 18, 2026, with the e-voting period ending on March 17, 2026.
💼 Action for Investors
Investors should assess whether the proposed remuneration and high percentage of profit-linked incentives are commensurate with the company's growth and industry standards. Pay close attention to the resolution regarding exceeding the 11% net profit limit for management compensation, as this can impact bottom-line returns for shareholders.
Lords Chloro Alkali Q3 FY26: PAT Surges 264% YoY to ₹4.61 Cr; Revenue Up 43.6%
Lords Chloro Alkali reported a robust YoY performance for Q3 FY26, with total income rising 43.6% to ₹94.11 crore and PAT increasing 264% to ₹4.61 crore. While YoY growth was strong, sequential margins were pressured by a hike in grid electricity tariffs effective October 2025, causing EBITDA margins to dip from 20.93% in Q2 to 11.56% in Q3. The company is aggressively pursuing a 'Green Chemical' strategy, with a 21 MW solar plant expected by March 2026 to mitigate power costs. A total capex of ₹355 crore is planned through FY28 to expand caustic soda and downstream CPW capacities.
Key Highlights
Q3 FY26 PAT grew by 263.96% YoY to ₹4.61 crore, while 9M FY26 PAT surged 573.53% to ₹24.10 crore.
Power and fuel costs as a percentage of production decreased from 51% in FY25 to 42% in 9M FY26 due to renewable energy integration.
Total income for 9M FY26 reached ₹295.35 crore, representing a 53.90% increase over the previous year.
Company is expanding Chlorinated Paraffin Wax (CPW) capacity from 50 TPD to 100 TPD by FY27 to enhance captive chlorine utilization.
A 21 MW solar project is scheduled for completion by March 2026 to provide cost visibility and margin stability.
💼 Action for Investors
Investors should monitor the commissioning of the 21 MW solar plant in March 2026, as it is the primary lever for restoring margins after the recent grid tariff hike. The company's transition toward downstream products and green energy makes it a compelling long-term play in the chloro-alkali sector.
Lords Chloro Alkali Q3 FY26 PAT Jumps 264% YoY to ₹4.61 Cr; 9M PAT Surges 574%
Lords Chloro Alkali reported a robust YoY performance for Q3 FY26 with total income rising 43.64% to ₹94.11 crore and PAT surging 263.96% to ₹4.61 crore. For the nine-month period (9M FY26), the company showed exceptional growth with PAT reaching ₹24.10 crore, a 573.53% increase over the previous year. However, on a sequential basis, EBITDA margins contracted from 20.93% in Q2 to 11.56% in Q3 due to a hike in electricity grid tariffs effective October 2025. Management anticipates margin recovery in FY27 following the commissioning of a 21 MW solar power plant in March 2026.
Key Highlights
9M FY26 Profit After Tax (PAT) reached ₹24.10 crore, representing a massive 573.53% YoY growth.
Total Income for 9M FY26 grew by 53.90% YoY to ₹295.35 crore, driven by a 38.54% increase in sales volumes.
Q3 FY26 EBITDA margin stood at 11.56%, a sequential drop from 20.93% in Q2 due to higher power costs.
Caustic Soda Lye (CSL) sales volumes for Q3 FY26 increased by 44.88% YoY to 20,956 MT.
The company is commissioning a 21 MW solar power plant by March 2026 to reduce dependence on high-cost grid power.
💼 Action for Investors
Investors should monitor the successful commissioning of the 21 MW solar plant in March 2026, as it is critical for restoring margins hit by recent power tariff hikes. The strong YoY volume growth and successful warrant subscription indicate healthy demand and a strengthened balance sheet for future expansion.
Lords Chloro Alkali Allots 35 Lakh Shares at Rs 122; Q3 Net Profit Jumps to Rs 4.61 Cr
Lords Chloro Alkali Limited has converted 35,00,000 warrants into equity shares at an issue price of Rs 122 each, aggregating to Rs 42.70 crore. This preferential allotment to promoters and select non-promoters has increased the total paid-up capital to 2.86 crore shares. Alongside the fundraise, the company reported a strong Q3 FY26 performance, with net profit rising significantly to Rs 4.61 crore from Rs 1.27 crore YoY. The board also approved the initiation of an ESOP scheme and the re-appointment of the Managing Director for a five-year term.
Key Highlights
Allotted 35,00,000 equity shares at Rs 122 per share (including Rs 112 premium) totaling Rs 42.70 crore
Q3 FY26 Net Profit surged to Rs 460.91 lakhs compared to Rs 126.64 lakhs in the same quarter last year
Revenue from operations for Q3 FY26 stood at Rs 9,395.22 lakhs, up from Rs 6,475.17 lakhs YoY
Promoter shareholding increased from 74.66% to 74.97% following the warrant conversion
Board approved the commencement of an Employee Stock Option Plan (ESOP) process
💼 Action for Investors
The conversion of warrants by promoters at a significant premium signals strong internal confidence in the company's valuation and future. Investors should view the robust quarterly earnings growth and capital infusion as positive indicators for long-term stability.
Lords Chloro Alkali Q3 Net Profit Jumps 264% YoY; Allots Shares Worth ₹42.70 Crore
Lords Chloro Alkali reported a robust Q3 FY26 with net profit surging 264% YoY to ₹4.61 crore, driven by a 45% increase in revenue from operations. The company successfully converted 35 lakh warrants into equity shares at ₹122 each, raising ₹42.70 crore and slightly increasing promoter stake to 74.97%. Additionally, the board approved the re-appointment of Managing Director Ajay Virmani for a five-year term and initiated the process for an Employee Stock Option Plan (ESOP).
Key Highlights
Net Profit for Q3 FY26 rose to ₹460.91 Lakhs, a 264% increase compared to ₹126.64 Lakhs in Q3 FY25.
Revenue from operations grew 45% YoY to ₹9,395.22 Lakhs for the quarter ended December 31, 2025.
Allotted 35,00,000 equity shares at ₹122 per share, aggregating to ₹42.70 Crores to promoters and non-promoters.
Promoter and promoter group shareholding increased from 74.66% to 74.97% post-allotment.
Mr. Ajay Virmani re-appointed as Managing Director for a 5-year term starting July 2026.
💼 Action for Investors
Investors should take note of the significant earnings growth and the promoter's increased stake as a sign of internal confidence. The stock may see positive momentum following the strong financial performance and successful capital infusion.
Lords Chloro Alkali Q3 Net Profit Jumps 264% to ₹4.61 Cr; Allots Shares Worth ₹42.7 Cr
Lords Chloro Alkali reported a robust performance for Q3 FY26, with revenue from operations growing 45% year-on-year to ₹93.95 crore. Net profit surged significantly to ₹4.61 crore compared to ₹1.27 crore in the same quarter last year. The company also completed a ₹42.70 crore fundraise through the conversion of 3.5 million warrants at ₹122 per share, which slightly increased promoter holding to 74.97%. Additionally, the board approved the re-appointment of MD Ajay Virmani for five years and initiated an ESOP scheme.
Key Highlights
Q3 FY26 Revenue from operations grew 45% YoY to ₹93.95 crore.
Net Profit for the quarter increased by 264% YoY to ₹4.61 crore from ₹1.27 crore.
Nine-month (9M FY26) Net Profit reached ₹24.10 crore, a massive jump from ₹3.58 crore in 9M FY25.
Allotted 35 lakh equity shares at ₹122 per share, raising ₹42.70 crore via warrant conversion.
Promoter and promoter group shareholding increased from 74.66% to 74.97% post-allotment.
💼 Action for Investors
The company demonstrates strong operational momentum and significant profit growth alongside a successful capital infusion. Investors should monitor the sustainability of these margins and the upcoming EGM on March 18, 2026, for approvals on managerial remuneration and ESOPs.
Lords Chloro Alkali Q3 Net Profit Jumps 264% YoY; Allots 35 Lakh Shares on Warrant Conversion
Lords Chloro Alkali reported a robust performance for Q3 FY26, with revenue from operations rising 45% YoY to ₹93.95 crore. Net profit surged significantly to ₹4.61 crore from ₹1.27 crore in the previous year's corresponding quarter. The company successfully converted 35 lakh warrants into equity shares at ₹122 per share, raising a total of ₹42.70 crore. Additionally, the board has approved the re-appointment of the Managing Director for a five-year term and initiated the process for an Employee Stock Option Plan (ESOP).
Key Highlights
Revenue from operations grew 45% YoY to ₹9,395.22 lakhs in Q3 FY26.
Net profit for the quarter increased by 264% YoY to ₹460.91 lakhs.
Allotted 35,00,000 equity shares at ₹122 each (including ₹112 premium) following warrant conversion.
Nine-month net profit reached ₹2,409.72 lakhs, a substantial increase from ₹357.76 lakhs in the prior year period.
Promoter and promoter group shareholding increased slightly to 74.97% post-allotment.
💼 Action for Investors
Investors should view the strong earnings growth and successful capital infusion as positive signs of operational efficiency and promoter confidence. However, keep an eye on the slight equity dilution and the upcoming EGM regarding managerial remuneration and ESOP approvals.